MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Ora H. Pescovitz purchased 7,693 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average price of $5.89 per share, for a total transaction of $45,311.77. Following the purchase, the director now owns 24,329 shares in the company, valued at $143,297.81. The trade was a 46.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.
MBX Biosciences Trading Down 2.0 %
Shares of MBX stock opened at $6.27 on Friday. MBX Biosciences, Inc. has a 1 year low of $4.81 and a 1 year high of $27.50. The stock has a 50 day simple moving average of $8.95 and a 200 day simple moving average of $15.66.
Institutional Trading of MBX Biosciences
Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in shares of MBX Biosciences in the fourth quarter worth $27,000. Virtus ETF Advisers LLC bought a new stake in MBX Biosciences during the fourth quarter worth about $64,000. Deutsche Bank AG acquired a new stake in MBX Biosciences during the fourth quarter worth about $80,000. Corebridge Financial Inc. bought a new position in MBX Biosciences in the 4th quarter valued at about $103,000. Finally, Wells Fargo & Company MN acquired a new position in shares of MBX Biosciences in the 4th quarter valued at approximately $108,000.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on MBX. JMP Securities started coverage on MBX Biosciences in a report on Thursday. They set a "market outperform" rating and a $38.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and issued a $44.00 price objective on shares of MBX Biosciences in a report on Thursday. Finally, Citizens Jmp initiated coverage on MBX Biosciences in a report on Thursday. They set an "outperform" rating and a $38.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $37.50.
View Our Latest Stock Report on MBX
MBX Biosciences Company Profile
(
Get Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
